Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer
Tóm tắt
Neutrophil to lymphocyte ratio (NLR), an index of systemic inflammation, has been associated with worse survival for many types of cancer. The aim of this study is to investigate the clinical significance of the blood NLR as a prognostic factor in non-small cell lung cancer (NSCLC) patients. Stage IV NSCLC patients diagnosed in our institution between April 2004 and March 2009 were retrospectively reviewed. Potential prognostic factors such as histology, gender, performance status, response to chemotherapy and NLR were analyzed. NLR was assessed baseline and during chemotherapy treatment. Overall survival (OS) and progression free survival (PFS) were calculated by the Kaplan–Meier method. A total of 171 patients were included in the study and 60 patients (35.1 %) presented a NLR ≥5. Median survival for the entire cohort was 9.3 months. We found that patients with undifferentiated carcinoma and patients with NLR ≥5 had a worse survival. Median PFS of patients with NLR <5 was 5.62 months and in patients with NLR ≥5 was 3.25 months (p = 0.098), and OS was 11.1 versus 5.6 months for patients with NLR<5 and NLR ≥5, respectively (p = 0.017). During the chemotherapy treatment, patients who normalized NLR after one cycle presented better outcomes (OS 8.7 vs. 4.3 months, p = 0.001, for patients who normalized NLR and for patients who remained persistently elevated). After multivariate analysis, histology and NLR remained independent predictors of survival (p < 0.05). In our analysis, elevated NLR is a predictor of shorter survival in patients with advanced NSCLC and the variation of NLR during the first cycle of treatment predicts survival. NLR is an easily measured, reproducible test that could be considered to be incorporated in the routine practice in NSCLC patients.
Tài liệu tham khảo
Jemal A, Siegel R, Ward E et al (2009) Cancer Statistics, 2009. CA Cancer J Clin 59:225–249
Groome PA, Bolejack V, Crowley JJ et al (2007) The IASLC Lung Cancer Staging Project: validation of the proposal for revision of the T, N and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol 2(8):694–705
Hoang T, Xu R, Schiller JH et al (2005) Clinical model to predict survival in chemo-naive patients with advanced non-small cell lung cancer treated with third generation chemotherapy regimen based on eastern cooperative oncology group data. J Clin Oncol 23(1):175–183
Mantovani A, Allavena P, Sica A, Ballkwill F (2008) Cancer-related inflammation. Nature 454:436–444
Leitch E, Chakrabarti M, Crozier J, McKee RF, Anderson JH, Horgan PG et al (2007) Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 97:1266–1270
McMillan D (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12:223–226
Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91:181–184
Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ et al (2008) Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 34:55–60
Gomez D, Morris-Stiff G, Toogood G, Lodge JP, Prasad KR (2008) Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 97:513–518
Kao S, Pavlakis N, Harvie R, Vardy J, Boyer M et al (2010) High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 16(23):5805–5813
Teramukai S, Kitano T, Kishida Y et al (2009) Pretreatment neutrophil counts as an independent prognostic factor in advanced non-small cell lung cancer—an analysis of Japan multinational trial organization LC00-03. Eur J Cancer 45:1950–1958
Sarraf KM, Belcher E, Raevsky E et al (2009) Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 137:425–428
Sakai T, Tsushima T, Kimura D, Hatanaka R, Yamada Y et al (2011) A clinical study of the prognostic factors for postoperative early recurrence in patients who underwent complete resection for pulmonary adenocarcinoma. Ann Thorac Cardiovasc Surg 17(6):539–543
Pacsmans M, Sculier JP, Libert P et al (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol 13:1221–1230
Greene FL (2002) American Joint Committee on Cancer, American Cancer Society, AJCC Cancer Staging Manual, 6th edn. Springer, New York
Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdall EK, Vauthey JN (2009) Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16:614–622
Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M (2010) Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with non-metastatic renal cell carcinoma. J Urol 184:873–878
An X, Ding PR, Li YH et al (2010) Elevated neutrophil-to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 15:516–522
Cho H, Hur HW, Kim SW et al (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58:15–23
Yamanaka T, Matsumoto S, Teramukai S et al (2007) The baseline ratio of neutrophil to lymphocyte is associated with patients prognosis in advanced cancer gastric. Oncology 73:215–220
Keizman D, Ish-Shalom M, Huang P, Eisenberger M, Pili R et al (2011) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitnib for metastatic renal cell carcinoma. Eur J Cancer 48(2):202–208